

In the Claims

Claims 1-24 (Cancelled)

Claim 25 (Currently amended): A method for the treatment or prevention of a condition associated with bacterial Group B *Streptococcal* infection, wherein said method comprises administering to a patient in need of such treatment or prevention, an immunogenically effective amount of a peptide encoded by a polynucleotide sequence wherein said polynucleotide sequence comprises a gene, obtainable from a Group B *Streptococcus*, selected from the group consisting of MS4, MS10, MS11, MS14 and MS16; or said polynucleotide sequence comprises a homologue or a functional fragment of one of said Group B *Streptococcus* genes an isolated bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase.

Claim 26 (Cancelled)

Claim 27 (Previously presented): The method, according to claim 25, wherein the infection is a local infection.

Claim 28 (Previously presented): The method, according to claim 25, wherein the infection is a urinary tract infection.

Claims 29-31 (Cancelled)

Claim 32 (New): The method, according to claim 25, wherein the isolated bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase comprises the amino acid sequence of SEQ ID NO:12.

Claim 33 (New): The method, according to claim 25, wherein the isolated bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is obtainable from a Group B *Streptococcus*.

Claim 34 (New): The method, according to claim 25, wherein the isolated bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is obtained from a Group B *Streptococcus*.

Claim 35 (New): The method, according to claim 25, wherein the isolated bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is obtainable from *Streptococcus mutans*.

Claim 36 (New): The method, according to claim 25, wherein the patient is human.

Claim 37 (New): A method for the treatment or prevention of a Group B *Streptococcal* infection, wherein said method comprises administering to a patient in need of such treatment or prevention, an immunogenically effective amount of an isolated peptide, wherein the peptide is an immunogenic fragment of a bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase.

Claim 38 (New): The method, according to claim 37, wherein the infection is a local infection.

Claim 39 (New): The method, according to claim 37, wherein the infection is a urinary tract infection.

Claim 40 (New): The method, according to claim 37, wherein the bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is obtainable from *Streptococcus mutans*.

Claim 41 (New): The method, according to claim 37, wherein the bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is obtainable from a Group B *Streptococcus*.

Claim 42 (New): The method, according to claim 37, wherein the bacterial NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is obtained from a Group B *Streptococcus*.

Claim 43 (New): The method, according to claim 37, wherein the immunogenic fragment is a fragment of SEQ ID NO:12.

Claim 44 (New): The method, according to claim 37, wherein the patient is human.

Claim 45 (New): A method for raising antibodies against Group B *Streptococcus*, comprising administering an isolated peptide comprising the amino acid sequence of SEQ ID NO:12 to a patient in need thereof, wherein the peptide is administered in an amount effective to produce the antibodies.

Claim 46 (New): The method, according to claim 45, wherein the patient is human.